Skip to main content
. Author manuscript; available in PMC: 2022 Dec 1.
Published in final edited form as: Transplant Cell Ther. 2021 Oct 2;27(12):993.e1–993.e8. doi: 10.1016/j.jtct.2021.08.031

Table 3.

Incidence of viral infections

HCT with G-CSF HCT without G-CSF p-value
CMV
 Within 3-months after HCT 32·1% (95% CI 28-37) 28·1% (95% CI 24-33) 0·196
 Within 6 months after HCT 33·9% (95% CI 30-38) 29·1% (95% CI 25-34) 0·123
EBV
 Within 3-months after HCT 17·7% (95% CI 14-21) 10·4% (95% CI 8-14) 0·002
 Within 6 months after HCT 19·1% (95% CI 16-23) 11·4% (95% CI 9-15) 0·002
Other*
 Within 3-months after HCT 22·5% (95% CI 19-27) 16·0% (95% CI 13-20) 0·013
 Within 6 months after HCT 26·1% (95% CI 22-30) 19·2% (95% CI 16-23) 0·016

Abbreviation:

HCT = hematopoietic cell transplant

G-CSF = granulocyte colony stimulating factor

CMV = Cytomegalovirus

EBV = Epstein Barr virus

*

Other includes adenovirus, herpesviridae and respiratory viruses.